Inhaled Corticosteroids In Copd The Case Against Homework

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2009http://www.goldcopd.org. Accessed Feb 24, 2010. [PubMed]

2. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J. 2009;34(1):13–16.[PubMed]

3. Postma DS, Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J. 2009;34(1):10–12.[PubMed]

4. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in COPD: a meta-analysis. Arch Intern Med. 2009;169(3):219–229.[PubMed]

5. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;1:742–750.[PubMed]

6. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest. 2000;117(Suppl 2):10S–14S.[PubMed]

7. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild COPD who continue smoking. European Respiratory Society Study on COPD. N Engl J Med. 1999;340:1948–1953.[PubMed]

8. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate COPD: a randomized controlled trial. Lancet. 1999;353:1819–1823.[PubMed]

9. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe COPD: the ISOLDE trial. BMJ. 2000;320:1297–1303.[PMC free article][PubMed]

10. Lung Health Study Research Group Effect of inhaled triamcino-lone on the decline in pulmonary function in COPD. N Engl J Med. 2000;343:1902–1909.[PubMed]

11. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in COPD. N Engl J Med. 2007;356(8):775–789.[PubMed]

12. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with COPD, Saskatchewan Canada. Ann Epidemiol. 2006;16(1):63–70.[PubMed]

13. Farr BM, Bartlett CL, Wadsworth J, Miller DL. British Thoracic Society Pneumonia Study Group. Risk factors for community-acquired pneumonia diagnosed upon hospital admission. Respir Med. 2000;94:954–963.[PubMed]

14. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J. 2006;28(2):346–351.[PubMed]

15. Dam TT, Harrison S, Fink HA, Ramsdell J, Barrett-Connor E. Osteoporotic Fractures in Men (MrOS) Research Group. Bone mineral density and fractures in older men with COPD or asthma. Osteporosis Int. 2009 Oct 9; [Epub ahead of print] [PMC free article][PubMed]

16. Loke YK, Kwok CS, Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD: a systematic review and meta-analysis. Eur Respir J. 2010;35(5):1003–1021.[PubMed]

17. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in COPD: a critical review and update. Curr Opin Pulm Med. 2010;16(2):118–122.[PMC free article][PubMed]

18. Loke YK, Singh S. Inhaled corticosteroids in patients with COPD. JAMA. 2009;301(14):1432–1434.[PubMed]

19. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for COPD. Cochrane Database of Systematic Reviews. 2007;4:CD006829.[PubMed]

20. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for COPD. Cochrane Database Syst Rev. 2007;(4):CD003794.[PMC free article][PubMed]

21. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: A systematic review. Chest. 2009;136(4):1029–1038.[PubMed]

22. Puhan MA, Bachmann LM, Kleijnen J, Ter Riet G, Kessels AG. Inhaled drugs to reduce exacerbations in patients with COPD: a network meta-analysis. BMC Med. 2009;14(7):2.[PMC free article][PubMed]

23. Sobieraj DM, White CM, Coleman CI. Benefits and risks of adjunctive inhaled corticosteroids in COPD: a meta-analysis. Clin Ther. 2008;30(8):1416–1425.[PubMed]

24. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable COPD: a systematic review and meta-analysis. JAMA. 2008;300(20):2407–2416.[PMC free article][PubMed]

25. Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008;31(5):927–933.[PubMed]

26. Sin D, Tashkin D, Xuekui Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet. 2009;374(9691):712–719.[PubMed]

27. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in COPD and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176(2):162–166.[PubMed]

28. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med. 2010;104(2):246–252.[PubMed]

29. GlaxoSmithKline Assessment of incidence of pneumonia among COPD patients with or without exposure to inhaled corticosteroids in General Practice Research Database. Available from: http://www.gsk-clinicalstudyregister.com/files/pdf/24060.pdf. Accessed Feb 24, 2010.

30. GlaxoSmithKline Assessment of incidence of pneumonia among COPD patients on seretide or inhaled corticosteroids in UK primary care. Available from: http://www.gsk-clinicalstudyregister.com/files/pdf/24056.pdf. Accessed Feb 24, 2010.

31. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641–647.[PubMed]

32. Etminan M, Sadatsafavi M, Ganjizade Zavareh S, Takkouche B, Fitzgerald JM. Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis. Drug Saf. 2008;31(5):409–414.[PubMed]

33. Hubbard RF, Tattersfield AF, Smith CF, et al. Use of inhaled corticosteroids and the risk of fracture. Chest. 2006;130:1687–1688.

34. Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med. 2002;166:1563–1566.[PubMed]

35. Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in COPD. Am J Respir Crit Care Med. 2004;169:855–859.[PubMed]

36. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest. 2007;13(5):1599–1560.[PubMed]

37. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001;345:941–947.[PubMed]

38. Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the towards a revolution in COPD health study. Chest. 2009;136(6):1456–1465.[PubMed]

39. Weatherall M, Clay J, James K, Perrin K, Shirtcliffe P, Beasley R. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology. 2009;14(7):983–990.[PubMed]

40. Uboweja A, Malhotra S, Pandhi P. Effect of inhaled corticosteroids on risk of development of cataract: a meta-analysis development of cataract: a meta-analysis. Fundam Clin Pharmacol. 2006;20(3):305–309.[PubMed]

41. Salpeter SR, Buckley NS. Systematic review of clinical outcomes in COPD: beta-agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol. 2006;31(2–3):219–230.[PubMed]

42. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. JAMA. 2008;300(12):1439–1450. (Erratum in JAMA 2009;301(12):1227–1230). [PubMed]

43. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166(3):333–339.[PubMed]

44. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010;137(1):13–19.[PubMed]

45. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed COPD. Ann Intern Med. 2008;149(6):380–390.[PubMed]

46. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer MUPLIFT Study Investigators A 4-year trial of tiotropium in COPD. N Engl J Med. 2008;359(15):1543–1554.[PubMed]

1. Postma DS, Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J 2009;34:10–12 [PubMed]

2. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009;34:13–16 [PubMed]

3. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–89 [PubMed]

4. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19–26 [PubMed]

5. Garbe E, LeLorier J, Boivin JF, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277:722–7 [PubMed]

6. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients [published erratum appears in JAMA 1998 Dec 2;280(21):1830] [see comments]. JAMA 1998;280:539–43 [PubMed]

7. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941–55 [PubMed]

8. Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003;112:469–78 [PubMed]

9. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162–6 [PubMed]

10. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010;123:1001–6 [PubMed]

11. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169:219–29 [PubMed]

12. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407–16 [PMC free article][PubMed]

13. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641–7 [PubMed]

14. Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011;139:505–12 [PubMed]

15. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144–9 [PubMed]

16. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;102:1099–108 [PubMed]

17. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009;6:320–9 [PubMed]

18. Chowdhury BA. Summary review of regulatory action: fluticasone propionate and salmeterol. Silver Spring, MD: Division of Pulmonary and Allergy Products, CDER, FDA; 2008

19. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009;374:712–19 [PubMed]

20. Halpin DM, Gray J, Edwards SJ, et al. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract 2011; 65:764–74 [PubMed]

21. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med 2010;16:118–22 [PMC free article][PubMed]

22. Ernst P, Baltzan M, Deschenes J, et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006;27:1168–74 [PubMed]

23. Suissa S, Baltzan M, Kremer R, et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004;169:83–8 [PubMed]

24. National Asthma and Prevention Program Guidelines for the diagnosis and management of asthma. Expert Panel Report 2. Bethesda, MD: National Heart, Lung and Blood Institute; 1997, NIH Publication No. 97-4051.

25. Boulet LP, Becker A, Berube D, et al. Canadian asthma consensus report, 1999. Can Med Assoc J 1999;161:s1–61 [PMC free article][PubMed]

26. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:628–34 [PubMed]

27. Grijalva CG, Kaltenbach L, Arbogast PG, et al. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford) 2010;49:82–90 [PMC free article][PubMed]

28. Sharafkhaneh A, Southard JG, Goldman M, et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 2012;106:257–68 [PubMed]

29. Patterson CM, Morrison RL, D'Souza A, et al. Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella Pneumoniae in mice. Respir Res 2012;13:40. [PMC free article][PubMed]

30. Hubner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am 2005;25:469–88 [PubMed]

31. Adams N, Bestall JM, Lasserson TJ, et al. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma. Cochrane Database Syst Rev 2004;(2):CD002310. [PubMed]

32. Esmailpour N, Hogger P, Rabe KF, et al. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997;10:1496–9 [PubMed]

33. Thorsson L, Edsbacker S, Kallen A, et al. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001;52:529–38 [PMC free article][PubMed]

34. O'Byrne PM, Pedersen S, Carlsson LG, et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 2011;183:589–95 [PubMed]

Categories: 1

0 Replies to “Inhaled Corticosteroids In Copd The Case Against Homework”

Leave a comment

L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *